Harbour Investments’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Harbour Investments’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,600	Closed	-$2K	–	3159
2022 Q3	$2K	Hold	3,600	–	–	﹤0.01%	2519
2022 Q2	$2K	Buy	+3,600	New	+$3.45K	﹤0.01%	2519

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Harbour Investments's PHAS Position: Q4 2022 in Review

Harbour Investments sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 3,600 shares — an estimated $2K sold.

Harbour Investments first reported a position in PHAS in Q2 2022 and held it in 2 quarters. The position peaked at $2K in Q3 2022. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

Harbour Investments reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Harbour Investments sold 3,600 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $2K.
Harbour Investments first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
Harbour Investments's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $2K in Q3 2022.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Harbour Investments's 13F filing for Q4 2022, filed 16 Feb 2023.